Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 2, 2005, Pages 151-156

  Zhang, Mei Yun ^a,b   Choudhry, Vidita ^a   Xiao, Xiaodong ^a   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Antibodies; Prophylaxis; S glycoprotein; S protein; SARS; Therapy; Treatment

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

B LYMPHOCYTE; CROSS REACTION; DRUG SYNTHESIS; EPSTEIN BARR VIRUS; HUMAN; IMMUNIZATION; IN VITRO STUDY; NONHUMAN; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TRANSGENIC MOUSE; VIRUS CULTURE; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULINS; MICE; MICE, TRANSGENIC; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL PROTEINS;

ANIMALIA; CORONAVIRUS;

EID: 17144382020     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Casadevall A, Dadachova E, Pirofski LA: Passive antibody therapy for infectious diseases. Nat Rev Microbiol (2004) 2 9):695-703.
2. Sawyer LA: Antibodies for the prevention and treatment of viral diseases. Antiviral Res (2000) 47(2):57-77.
3. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV: Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci (2004) 25(6):306-310.
4. DesJardin JA, Snydman DR: Antiviral immunotherapy: A review of current status. Biodrugs (1998) 9(6):487-507
5. Wong VW, Dai D, Wu AK, Sung JJ: Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J (2003) 9(3):199-201.
6. Pearson H, Clarke T, Abbott A, Knight J, Cyranoski D: SARS: What have we learned? Nature (2003) 424 6945):121-126.
7. Burnouf T, Radosevich M: Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J (2003) 9(4):309.
8. Ali MB: Treating severe acute respiratory syndrome with hyperimmune globulins. Hong Kong Med J (2003) 9 5):391-392.
9. Casadevall A: Passive antibody therapies: Progress and continuing challenges. Clin Immunol (1999) 93(1):5-15.
10. Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC: Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect (2004) 10(12):1062-1066.
11. Nie Y, Wang G, Shi X, Zhang H, Qiu Y, He Z, Wang W, Lien G, Yin X, Du L, Ren L et al.: Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis (2004) 190(6):1119-1126.
12. Shi Y, Wan Z, Li L, Li P, Li C, Ma Q, Cao C: Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients. J Clin Virol (2004) 31(1):66-68.
13. Han DP, Kim HG, Kim YB, Poon LL, Cho MW: Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology (2004) 326(1):140-149.
14. Guo JP, Petric M, Campbell W, McGeer PL: SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. Virology (2004) 324(2):251-256.
15. Hofmann H, Hattermann K, Marzi A, Gramberg T, Geier M, Krumbiegel M, Kuate S, Uberla K, Niedrig M, Pohlmann S: S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol (2004) 78(12):6134-6142.
16. Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, Packard M, Shieh WJ, Zaki S, Murphy B: Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol (2004) 78(7):3572-3577.
17. Roberts A, Vogel L, Guarner J, Hayes N, Murphy B, Zaki S, Subbarao K: Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol (2005) 79(1):503-511.
18. McAuliffe J, Vogel L, Roberts A, Fahle G, Fischer S, Shieh WJ, Butler E, Zaki S, St Claire M, Murphy B, Subbarao K: Replication of SARS coronavirus administered into the respiratory tract of African green, rhesus and cynomolgus monkeys. Virology (2004) 330 1):8-15.
19. Zhou T, Wang H, Luo D, Rowe T, Wang Z, Hogan RJ, Qiu S, Bunzel RJ, Huang G, Mishra V, Voss TG et al: An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. J Virol (2004) 78 13):7217-7226.
20. Zhang H, Wang G, Li J, Nie Y, Shi X, Lian G, Wang W, Yin X, Zhao Y, Qu X, Ding M et al: Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol (2004) 78(13):6938-6945.
21. Yao YX, Ren J, Heinen P, Zambon M, Jones IM: Cleavage and serum reactivity of the severe acute respiratory syndrome coronavirus spike protein. J Infect Dis (2004) 190(1):91-98.
22. Zeng F, Chow KY, Hon CC, Law KM, Yip CW, Chan KH, Peiris JS, Leung FC: Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. Biochem Biophys Res Commun (2004) 315(4):1134-1139.
23. Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ: A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature (2004) 428 6982):561-564.
24. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B: Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA (2004) 101 17):6641-6646.
25. Qu D, Zheng B, Yao X, Guan Y, Yuan ZH, Zhong NS, Lu LW, Xie JP, Wen YM: Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavinus) induced local and serum antibodies in mice. Vaccine (2005) 23(7):924-931.
26. Xiong S, Wang YF, Zhang MY, Liu XJ, Zhang CH, Liu SS, Qian CW, Li JX, Lu JH, Wan ZY, Zheng HY et al: Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett (2004) 95 2):139-143.
27. He Y, Zhou Y, Wu H, Luo B, Chen J, Li W, Jiang S: Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: Implication for developing SARS diagnostics and vaccines. J Immunol (2004) 173 6):4050-4057.
28. Takasuka N, Fujii H, Takahashi Y, Kasai M, Morikawa S, Itamura S, Ishii K, Sakaguchi M, Ohnishi K, Ohshima M, Hashimoto S et al: A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol (2004) 16(10):1423-1430.
29. Tang L, Zhu Q, Qin E, Yu M, Ding Z, Shi H, Cheng X, Wang C, Chang G, Zhu Q, Fang F et al: Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol (2004) 23(6):391-394.
30. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL: Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA (2004) 101(26):9804-9809.
31. He Y, Zhou Y, Siddiqui P, Jiang S: Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun (2004) 325(2):445-452.
32. Pang H, Liu Y, Han X, Xu Y, Jiang F, Wu D, Kong X, Bartlam M, Rao Z: Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: Implications for the design of an effective protein-based vaccine. J Gen Virol (2004) 85 10):3109-3113.
33. Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, Smith G, Jones S, Proulx R, Deschambault Y, Grudeski E et al: Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol (2004) 78 22):12672-12676.
34. Weingartl HM, Copps J, Drebot MA, Marszal P, Smith G, Gren J, Andova M, Pasick J, Kitching P, Czub M: Susceptibility of pigs and chickens to SARS coronavirus. Emerg Infect Dis (2004) 10 2):179-184.
35. Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S, Gambotto A: Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet (2003) 362 9399):1895-1896.
36. Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, Murphy BR, Subbarao K, Collins PL: Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet (2004) 363 9427):2122-2127.
37. Xiao X, Dimitrov DS: The SARS-CoV S glycoprotein. Cell Mol Life Sci (2004) 61(19-20):2428-2430.
38. Berry JD, Jones S, Drebot MA, Andonov A, Sabara M, Yuan XY, Weingartl H, Fernando L, Marszal P, Gren J, Nicolas B et al: Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J Virol Methods (2004) 120(1):87-96.
39. Gubbins MJ, Plummer FA, Yuan XY, Johnstone D, Drebot M, Andonova M, Andonov A, Berry JD: Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus. Mol Immunol (2005) 42(1):125-136.
40. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A: An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat Med (2004) 10 8):871-875.
41. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico AS, Olurinde M, Choe H, Anderson LJ et al: Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA (2004) 101(8):2536-2541.
42. ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, Haagmans BL, Kuiken T, de Kruif J, Preiser W, Spaan W, Gelderblom HR et al: Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet (2004) 363 9427):2139-2141.
43. van den Brink EN, Ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, Throsby M, Marissen WE, Rood PM, Bakker AB, Gelderblom HR, Martina BE et al: Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol (2005) 79(3):1635-1644.
44. Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD Jr, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K et al: Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis (2005) 191(4):507-514.
45. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H et al Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature (2003) 426(6965):450-454.
46. Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K, Dimitrov DS: The SARS-CoV S glycoprotein: Expression and functional characterization. Biochem Biophys Res Commun (2003) 312 4):1159-1164.
47. Wong SK, Li W, Moore MJ, Choe H, Farzan M: A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem (2004) 279 5):3197-3201.
48. Babcock GJ, Esshaki DJ, Thomas WD Jr, Ambrosino DM: Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol (2004) 78(9):4552-4560.
49. Dimitrov DS: The secret life of ACE2 as a receptor for the SARS virus. Cell (2003) 115(6):652-653.
50. Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S: Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet (2004) 363(9413):938-947.
51. Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ: Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci USA (2004) 101(22):8455-8460.
52. Zhu J, Xiao G, Xu Y, Yuan F, Zheng C, Liu Y, Yan H, Cole DK, Bell JI, Rao Z, Tien P et al: Following the rule: Formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochem Biophys Res Commun (2004) 319 1):283-288.
53. Tripet B, Howard MW, Jobling M, Holmes RK, Holmes KV, Hodges RS: Structural characterization of the SARS-coronavirus spike S fusion protein core. J Biol Chem (2004) 279(20):20836-20849.
54. Yang ZY, Werner HC, Kong WP, Leung K, Traggiai E, Lanzavecchia A, Nabel GJ: Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA (2005) 102(3):797-801.